Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid versus placebo in pediatric biliary atresia after successful Kasai procedure
NL-OMON59843Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary atresia comparing Obeticholic acid + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first composite clinical worsening event. Started Apr 2024; status: completed.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NL-OMON59843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59843.